Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025
본 보고서에서는 제약 및 생명공학 분야의 전임상 단계 제휴 조건 및 계약에 대해 조사했으며 기업이 전임상 단계의 제휴 계약을 체결하는 방법과 이유 및 이러한 계약을 지원하는 재무적·전략적 조건에 대해 데이터를 바탕으로 종합적으로 분석했습니다. 또한 이 보고서는 제약 및 생명공학 업계에서 초기 단계의 제휴를 정의하는 구조, 협상 역학 및 재무 고려 사항에 대한 깊은 인사이트를 제공합니다.
전임상 단계에서 라이선싱 계약은 일반적으로 라이센시에게 라이센서의 의약품 후보 및 기술을 추가로 개발할 권리 또는 옵션을 부여합니다. 이러한 계약은 종종 다면적이며 공동 연구 개발에서 시작하여 상업화 계약에 이르기도합니다.
이 보고서는 의료 분야에서 최신 전임상 단계 계약의 상세한 내역을 제공하고, 기업이 시장 동향을 파악하고, 경쟁 계약 구조를 평가하고, 자사의 협상 전략을 최적화하는 데 도움이 됩니다.
이 보고서는 다음 내용을 제공합니다.
- 2020년 이후 바이오제약 업계에 있어서 전임상 단계의 거래 동향의 분석
- 선불, 마일스톤, 로열티 등을 포함한 자세한 거래 구조
- 실제 전임상 단계 계약에 관한 사례 연구
- 1,670건 이상의 전임상 단계 안건에 액세스가 가능
- 2020년 이후 가장 활발한 전임상 단계의 딜메이커 프로파일
- 최고액의 전임상 단계 안건 상세 분석
목차
주요 요약
제1장 서론
제2장 기업이 전임상 단계의 화합물로 제휴를 하는 이유는 무엇인가?
- 전임상 단계의 제휴의 역할
- 전임상 단계에서의 라이선스 도입
- 전임상 단계에서의 라이선스 공여
- 디스커버리 단계, 전임상 단계, 임상 단계의 거래의 차이
- 전임상 단계의 제휴 계약을 체결하는 이유
- 라이센서가 전임상 단계의 거래에 진입하는 이유
- 라이센시가 전임상 단계의 거래에 진입하는 이유
- 전임상 단계의 제휴 계약의 장래
제3장 전임상 단계의 거래 전략과 구조
- 기업은 어느 단계에서 제휴할까?
- 제약 및 생명공학 분야에서의 조기 제휴
- 제약 및 생명공학 분야에서의 제휴
- 초기 단계와 후기 단계의 제휴 : 위험과 비용 비교
- 기업은 전임상 단계의 제휴에 얼마를 소비하고 있는가?
- 순수한 제휴 계약과 복수 구성 요소 제휴 계약
- 순수한 라이선싱 계약 구조
- 순수한 전임상 단계의 라이선싱 계약의 예
- 사례 연구
- 복수 구성 요소 전 임상 단계의 제휴 계약
- 복수 구성 요소 전임상 단계 조항의 예
- 사례 연구
제4장 전임상 단계의 제휴 지불 전략
- 전임상 단계의 지불 전략
- 지불 옵션
- 헤드라인 값
- 선불 결제
- 대출
- 전환 대출
- 지분
- 연구개발자금
- 라이선싱 비용
- 마일스톤 지급
- 로열티 지급
- 가격
- 옵션 지급
제5장 전임상 단계의 거래 동향
- 1년 이상의 전임상 단계 제휴
- 전임상 단계의 제휴 : 거래 유형별
- 전임상 단계의 제휴 : 질환 유형별
- 전임상 단계의 제휴 : 기술 유형별
- 가장 활발한 기업에 의한 전임상 단계의 제휴
제6장 전임상 단계의 제휴에 있어서 지불 조건
- 전임상 단계의 지불 조건에 관한 가이드라인
- 전임상 단계의 지불 조건 : 거래 데이터 분석
- 지불 조건 분석
- 전임상 단계의 헤드라인액
- 전임상단계 계약의 업프론트 지불
- 전임상 단계 계약의 마일스톤 지불
- 전임상 단계의 충성도
제7장 주요 전임상 단계의 거래
제8장 단계의 딜메이커 상위 25개사
- 가장 활발한 전임상 단계의 딜메이커 상위 25개사
제9장 전임상 단계의 제휴 계약 디렉토리
- 계약에 관한 전임상 단계의 거래(2020-2025년)
제10장 전임상단계 거래 : 개발단계별
부록
KTH
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025 report provides a comprehensive, data-driven analysis of how and why companies enter preclinical-stage partnering agreements, as well as the key financial and strategic terms shaping these partnerships. This essential industry resource delivers unparalleled insights into the structure, negotiation dynamics, and financial considerations that define early-stage pharmaceutical and biotech collaborations.
At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements.
This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.
A Must-Have Resource for Biotech and Pharma Dealmakers
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.
With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:
- Benchmarking deal structures and financial terms
- Optimizing negotiation strategies
- Assessing potential partners' flexibility
- Identifying trends in preclinical-stage partnerships
- Why This Report is Essential for Dealmakers
- Understanding a potential partner's negotiation flexibility and deal structures is critical when entering preclinical-stage partnerships. While headline financial figures (e.g., upfront payments, milestones, royalties) are important, contract documents reveal the precise triggers and conditions for these payments-details that are often missing from press releases and traditional deal databases.
- This report provides a comprehensive listing of over 1,670 preclinical-stage deals announced since 2020, including financial terms where available. Additionally, it includes direct links to online deal records, along with publicly available contract documents submitted to the SEC.
- By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
- Comprehensive Analysis of Preclinical-Stage Partnering Trends
The first chapters of this report offer a detailed orientation to preclinical-stage deal-making, including:
Chapter 1 - Introduction to the report
Chapter 2 - Why companies engage in preclinical-stage partnerships
Chapter 3 - Strategic approaches and deal structures, with case studies
Chapter 4 - Payment strategies, including upfronts, milestones, and royalties
Chapter 5 - Analysis of preclinical-stage deal activity (2020-2025), categorized by year, stage of development, therapeutic area, technology type, and key dealmakers
Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates
Chapter 7 - A review of the leading preclinical-stage deals by headline value
Chapter 8 - Profiles of the top 25 most active preclinical-stage dealmakers
Chapter 9 - A database of preclinical-stage partnering agreements, including contract documents where available
Chapter 10 - A comprehensive directory of all preclinical-stage deals announced since 2020
- Key Benefits of the Report
This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own preclinical-stage partnerships. Key benefits include:
- Time-Saving Market Intelligence - Eliminate the need for manual research with ready-to-use insights on industry trends and deal structures.
- Unmatched Financial Data Access - Gain exclusive insight into headline values, upfront payments, milestone structures, and royalty terms to optimize negotiations.
- Comprehensive Deal Database - Access over 1,670 preclinical-stage agreements, including contract documents where available.
- Deep-Dive into Industry Leaders - Analyze actual preclinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging players.
- Strategic Case Studies & Deal Analysis - Examine real-world deal structures and negotiation strategies to enhance your own business development approach.
- High-Value Deal Identification - Pinpoint the most lucrative preclinical-stage deals signed since 2020, gaining insight into premium industry transactions.
- Profile the Most Active Dealmakers - Identify key players driving preclinical-stage collaborations, ensuring you engage with the right partners.
- Full Deal Listings & Categorization - Navigate a complete A-Z listing of preclinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
- Negotiate with Confidence - Understand the key terms and conditions agreed upon in previous deals, helping you structure optimal agreements.
- Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms.
- Scope of the Report
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:
- Trends in preclinical-stage dealmaking in the biopharma industry since 2020
- Detailed deal structures, including upfront, milestone, and royalty terms
- Case studies of real-life preclinical-stage agreements
- Access to over 1,670 preclinical-stage deals, with contract records where available
- Profiles of the most active preclinical-stage dealmakers since 2020
- Analysis of the highest-value preclinical-stage deals
Each deal record is indexed by:
- Company (A-Z)
- Headline Value
- Deal Type
- Specific Therapy Focus
- Technology Focus
- Critical Questions Answered
By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:
- What specific rights are granted in each agreement?
- What exclusivity terms apply?
- How is the deal structured financially? (Upfronts, milestones, royalties)
- Who controls development, manufacturing, and commercialization?
- How are intellectual property rights handled?
- What are the termination conditions for the agreement?
- What dispute resolution mechanisms are in place?
- How are confidentiality and publication rights managed?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Why do companies partner preclinical stage compounds?
- 2.1. Introduction
- 2.2. The role of preclinical stage partnering
- 2.2.1. In-licensing at preclinical stage
- 2.2.2. Out-licensing at preclinical stage
- 2.3. Difference between discovery, preclinical and clinical stage deals
- 2.4. Reasons for entering into preclinical stage partnering deals
- 2.4.1. Licensors reasons for entering preclinical stage deals
- 2.4.2. Licensees reasons for entering preclinical stage deals
- 2.5. The future of preclinical stage partnering deals
Chapter 3 - Preclinical stage deal strategies and structure
- 3.1. Introduction
- 3.2. At what stage do companies partner?
- 3.2.1. Partnering early in pharmaceutical / biotech
- 3.2.1.1. Discovery and preclinical stage partnering case studies
- 3.2.1.1.a. Case study 1
- 3.2.1.1.b. Case study 2
- 3.2.1.1.c. Case study 3
- 3.2.1.1.d. Case study 4
- 3.2.2. Partnering later in pharmaceutical/biotech
- 3.2.2.1. Clinical stage partnering case studies
- 3.2.2.1.a. Case study 5
- 3.2.2.1.b. Case study 6
- 3.2.2.1.c. Case study 7
- 3.2.2.1.d. Case study 8
- 3.3. Early and later stage partnering - a risk/cost comparison
- 3.4. What do companies spend on preclinical stage partnering?
- 3.5. Pure versus multi-component partnering deals
- 3.6. Pure licensing agreement structure
- 3.6.1. Example pure preclinical stage licensing agreements
- 3.6.1.a. Case study 9
- 3.6.1.b. Case study 10
- 3.7. Multicomponent preclinical stage partnering agreements
- 3.7.1. Example multicomponent preclinical stage clauses
- 3.7.1.a. Case study 11
- 3.7.1.b. Case study 12
Chapter 4 - Preclinical stage partnering payment strategies
- 4.1. Introduction
- 4.2. Preclinical stage payment strategies
- 4.3. Payment options
- 4.3.1. Headline values
- 4.3.2. Upfront payments
- 4.3.2.1. Conditionality of upfront payments
- 4.3.3. Loans
- 4.3.4. Convertible loans
- 4.3.5. Equity
- 4.3.6. R&D funding
- 4.3.7. Licensing fees
- 4.3.8. Milestone payments
- 4.3.9. Royalty payments
- 4.3.9.1. Issues affecting royalty rates
- 4.3.9.2. Royalties on combination products
- 4.3.9.2.a. Case study 13
- 4.3.9.3. Guaranteed minimum/maximum annual payments
- 4.3.9.4. Royalty stacking
- 4.3.9.5. Royalties and supply/purchase contracts
- 4.3.10. Quids
- 4.3.11. Option payments
Chapter 5 - Trends in preclinical stage deal making
- 5.1. Introduction
- 5.2. Preclinical stage partnering over the year
- 5.2.1. Attributes of preclinical deals
- 5.3. Preclinical stage partnering by deal type
- 5.4. Preclinical stage partnering by disease type
- 5.5. Partnering by preclinical stage technology type
- 5.6. Preclinical stage partnering by most active company, 2020 - 2025
Chapter 6 - Payment terms for preclinical stage partnering
- 6.1. Introduction
- 6.2. Guidelines for preclinical stage payment terms
- 6.2.1. Upfront payments
- 6.2.2. Milestone payments
- 6.2.3. Royalty payments
- 6.3. Preclinical stage payment terms - deal data analysis
- 6.3.1. Public data
- 6.3.2. Survey data
- 6.4. Payment terms analysis
- 6.4.1. Preclinical stage headline values
- 6.4.2. Preclinical stage deal upfront payments
- 6.4.3. Preclinical stage deal milestone payments
- 6.4.4. Preclinical stage royalty rates
Chapter 7 - Leading preclinical stage deals
- 7.1. Introduction
- 7.2. Top preclinical stage deals by value
Chapter 8 - Top 25 most active preclinical stage dealmakers
- 8.1. Introduction
- 8.2. Top 25 most active preclinical stage dealmakers
Chapter 9 - Preclinical stage partnering contracts directory
- 9.1. Introduction
- 9.2. Preclinical stage deals with contracts 2020 - 2025
Chapter 10 - Preclinical stage deal making by development stage
- 10.1. Introduction
- 10.2. Deals by preclinical stage
Appendices
- Appendix 1 - Preclinical stage dealmaking by companies A-Z
- Appendix 2 - Preclinical stage dealmaking by industry sector
- Appendix 3 - Preclinical stage dealmaking by stage of development
- Appendix 4 - Preclinical stage dealmaking by therapy area
- Appendix 5 - Preclinical stage dealmaking by technology type
- About Biopharma Research Ltd
- Current Partnering
- Current Agreements
- Recent titles from Current Partnering
Table of figures
- Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
- Figure 2: Components of the pure licensing deal structure
- Figure 3: Payment options for preclinical stage partnering deals
- Figure 4: Issues affecting royalty rates
- Figure 5: Preclinical stage partnering frequency 2020 - 2025
- Figure 6: Preclinical stage partnering by deal type since 2020
- Figure 7: Preclinical stage partnering by disease type since 2020
- Figure 8: Preclinical stage partnering by technology type since 2020
- Figure 9: Top 25 most active preclinical stage dealmakers, 2020 - 2025
- Figure 10: Review of upfront payments for preclinical stage deals
- Figure 11: Review of milestone payments for preclinical stage deals
- Figure 12: Review of royalty payments for preclinical stage deals
- Figure 13: Preclinical stage deals with a headline value
- Figure 14: Preclinical stage deals with an upfront value
- Figure 15: Preclinical stage deals with a milestone value
- Figure 16: Preclinical stage deals with a royalty rate value
- Figure 17: Top preclinical stage deals by value since 2020
- Figure 18: Most active preclinical stage dealmakers 2020 - 2025
